The primary outcome measures were
changes in the visual analog pain scale (VAS) and changes in the neuropathic pain scale (NPS).
WBV demonstrated a significant (p < 0.05) acute pain reduction in the VAS, and a significant
chronic reduction in both the VAS and NPS scales.